AMPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Amphastar Pharmaceuticals's Gross Profit for the three months ended in Dec. 2024 was $86.6 Mil. Amphastar Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $186.5 Mil. Therefore, Amphastar Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2024 was 46.45%.
The historical rank and industry rank for Amphastar Pharmaceuticals's Gross Margin % or its related term are showing as below:
During the past 13 years, the highest Gross Margin % of Amphastar Pharmaceuticals was 54.49%. The lowest was 30.75%. And the median was 40.95%.
Amphastar Pharmaceuticals had a gross margin of 46.45% for the quarter that ended in Dec. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Amphastar Pharmaceuticals was 6.00% per year.
The historical data trend for Amphastar Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
40.97 | 45.63 | 49.87 | 54.49 | 51.08 |
Amphastar Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
53.98 | 52.43 | 52.18 | 53.31 | 46.45 |
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue.
Amphastar Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as
Gross Margin % (A: Dec. 2024 ) | = | Gross Profit (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | 373.9 | / | 731.967 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (731.967 - 358.112) | / | 731.967 | |
= | 51.08 % |
Amphastar Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2024 is calculated as
Gross Margin % (Q: Dec. 2024 ) | = | Gross Profit (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | 86.6 | / | 186.523 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (186.523 - 99.875) | / | 186.523 | |
= | 46.45 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Amphastar Pharmaceuticals (NAS:AMPH) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Amphastar Pharmaceuticals had a gross margin of 46.45% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Floyd F. Petersen | director | 11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
William J Peters | officer: CFO, SVP & Treasurer | C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
Rong Zhou | officer: EVP, Production | C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730 |
Richard K Prins | director | |
Yakob Liawatidewi | officer: SVP Corp Admin Center | C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730 |
Michael A Zasloff | director | |
Mary Z. Luo | director, 10 percent owner, officer: COO and Chief Scientist | 11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
Gayle Deflin | director | 11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
Diane G. Gerst | officer: EVP, QA & Regulatory Affairs | 11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
Howard Lee | director | 13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000 |
Jack Y. Zhang | director, 10 percent owner, officer: CEO & Chief Scientific Officer | 11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
David Maris | director | C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
Richard Koo | director | 11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
Jason B. Shandell | director, officer: President | 11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
Applied Physics & Chemistry Laboratories, Inc. | 10 percent owner | 13760 MAGNOLIA AVENUE, CHINO CA 91710 |
From GuruFocus
By GuruFocus News • 11-07-2024
By GuruFocus News • 02-28-2025
By ACCESSWIRE • 11-07-2024
By ACCESSWIRE • 01-08-2025
By ACCESSWIRE • 11-14-2024
By ACCESSWIRE • 10-29-2024
By ACCESSWIRE • 02-21-2025
By GuruFocus News • 03-19-2025
By ACCESSWIRE • 03-05-2025
By GuruFocus News • 03-05-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.